Blueprint Medicines Corp expected to post a loss of 52 cents a share - Earnings Preview

Blueprint Medicines

29/04/2025 14:13

Blueprint Medicines Corp BPMC.OQ BPMC.O is expected to show a rise in quarterly revenue when it reports  results on May 1 for the period ending March 31 2025

The Cambridge Massachusetts-based  company is expected to report a 61.9% increase in revenue to $155.607 million from $96.12 million a year ago, according to the mean estimate from 19 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Blueprint Medicines Corp is for a loss of 52 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 0.7% in the last three months. ​

Wall Street's median 12-month price target for Blueprint Medicines Corp is $130.00​, above​ its last closing price of $88.51. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.68
-0.70
-0.79
Missed
-12.3
Sep. 30 2024
-0.92
-0.97
-0.89
Beat
7.9
Jun. 30 2024
-1.30
-1.29
-0.80
Beat
38​
Mar. 31 2024
-1.65
-1.66
-1.32
Beat
20.6
​​Dec. 31 2023
-2.06
-2.04
-1.82
Beat
10.8
Sep. 30 2023
-2.33
-2.37
-2.20
Beat
7.1​
Jun. 30 2023
-2.54
-2.54
-2.19
Beat
13.8
Mar. 31 2023
-2.69
-2.67
-2.15
Beat
19.5

This summary was machine generated April 29 at 13:13 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)